3 Apr 2017 07:00
Grant of share options to Directors
3 April 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has granted share options ("Options") to certain of its executive directors to acquire a total of 554,597 ordinary shares of 5.0p each in the capital of the Company ("Ordinary Shares") under the Silence Therapeutics Plc share option scheme.
.
Director | Options Granted | Total Number of Options held following Grant | Total Number of Options held as % of issued share capital |
Ali Mortazavi, CEO | 242,222 | 3,970,300 | 5.7% |
David Ellam, CFO | 312,375 | 512,375 | 0.7% |
These Options have been granted as nil cost options vesting after a period of three years from grant. The Options are subject to achievement of certain performance conditions within the three years from grant, on the basis of 33% vesting for a share price of £1.35, a further 33% vesting for a share price of £1.50, and the final 34% for a share price of £1.60. The share price must be maintained for a period of 30 continuous days. The Options are exercisable over the period of 10 years from the date of grant. Claw-back and malus provisions apply.
Following these grants the Company has a total of 6,047,583 share options outstanding representing 8.7% of the existing issued share capital of the Company.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Ali Mortazavi |
2 | Reason for the notification | |
a) | Position/status | Chief Executive Officer |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Silence Therapeutics Plc |
b) | LEI | N/A |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument
Identification code | Options over Ordinary Shares
ISIN for Silence Therapeutics plc Ordinary Shares GB00B9GTXM62 |
b) | Nature of the transaction | Grant of Options under the Silence Therapeutics Plc Share Option Plan |
c) | Price(s) and volume(s) | Price(s) Volume(s)
Nil 242,222
|
d) | Aggregated information
- Aggregated volume
- Price | 242,222 Options Nil cost |
e) | Date of the transaction | 31 March, 2017 |
f) | Place of the transaction | Outside a trading venue |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | David Ellam |
2 | Reason for the notification | |
a) | Position/status | Chief Financial Officer |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Silence Therapeutics plc |
b) | LEI | N/A |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Options over Ordinary Shares |
Identification code | ISIN for Silence Therapeutics plc Ordinary Shares GB00B9GTXM62 | |
b) | Nature of the transaction | Grant of Options under the Silence Therapeutics Plc Share Option Plan |
c) | Price(s) and volume(s) | Price(s) Volume(s)
Nil 312,375
|
d) | Aggregated information
- Aggregated volume
- Price | 312,375 Options Nil cost |
e) | Date of the transaction | 31 March 2017 |
f) | Place of the transaction | Outside a trading venue |
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer
| Tel: +44 (0)20 3457 6900 |
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Henry Fitzgerald-O'Connor/Emma Gabriel
| Tel: +44 (0)20 7523 8350 |
Peel Hunt LLP (Joint Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert
| Tel: +44 (0) 20 3727 1000 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
SLN.L (SLN)